NB100-2339

antibody from Novus Biologicals

Targeting: MCM2 BM28, CCNL1, cdc19, CDCL1, D3S3194, DFNA70, KIAA0030

Western blot (Supportive data in Antibodypedia)

Immunohistochemistry (Supportive data in Antibodypedia)

Antibody Data

Product number

NB100-2339

Provider

Novus Biologicals

Proper citation

Novus Cat#NB100-2339, RRID:AB_10001214

Product name

Rabbit Polyclonal MCM2 Antibody

Antibody type

Polyclonal

Description

Immunogen affinity purified.

Reactivity

Human, Mouse

Host

Rabbit

Isotype

IgG

Vial size

0.1 ml

Concentration

0.2 mg/ml

Storage

Store at 4C. Do not freeze.

References

Submitted references

Molecular mechanism of activation of human Cdc7 kinase: bipartite interaction with Dbf4/activator of S phase kinase (ASK) activation subunit stimulates ATP binding and substrate recognition.

Kitamura R, Fukatsu R, Kakusho N, Cho YS, Taniyama C, Yamazaki S, Toh GT, Yanagi K, Arai N, Chang HJ, Masai H
The Journal of biological chemistry 2011 Jul 1;286(26):23031-43

---

Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers.

Rodriguez-Acebes S, Proctor I, Loddo M, Wollenschlaeger A, Rashid M, Falzon M, Prevost AT, Sainsbury R, Stoeber K, Williams GH
The American journal of pathology 2010 Oct;177(4):2034-45

---

Transcriptional co-activator LEDGF interacts with Cdc7-activator of S-phase kinase (ASK) and stimulates its enzymatic activity.

Hughes S, Jenkins V, Dar MJ, Engelman A, Cherepanov P
The Journal of biological chemistry 2010 Jan 1;285(1):541-54

---

Loss of anchorage in checkpoint-deficient cells increases genomic instability and promotes oncogenic transformation.

Cremona CA, Lloyd AC
Journal of cell science 2009 Sep 15;122(Pt 18):3272-81

---

Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma.

Kulkarni AA, Kingsbury SR, Tudzarova S, Hong HK, Loddo M, Rashid M, Rodriguez-Acebes S, Prevost AT, Ledermann JA, Stoeber K, Williams GH
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Apr 1;15(7):2417-25

Western blot

Supportive validation

Submitted by

Novus Biologicals (provider)

Main image

Experimental details

Western Blot: MCM2 [p Ser53] Antibody [NB100-2339] - Whole cell lysate (50 ug) from asynchronous 293T cells that was mock treated (-) or treated (+) with phosphatases (PPase). Antibody used at 0.1 ug/ml. To examine total MCM2, the blot was stripped and then blotted with rabbit anti-MCM2 antibody at 0.1 ug/ml.

Supportive validation

Submitted by

Novus Biologicals (provider)

Main image

Experimental details

Western Blot: MCM2 [p Ser53] Antibody [NB100-2339] - Detection of Human Phospho MCM2 (S53) by Western Blot. Samples: Whole cell lysate (5 and 15 ug for WB; 1 mg for IP, 20% of IP loaded) from asynchronous 293T cells. For IP/WB, MCM2 was immunoprecipitated using A300-191A, which recognizes total MCM2. The immunoprecipitate was mock treated (-) or treated (+) with phosphatase (PPase). Antibody: Affinity purified rabbit anti-phospho MCM2 (S53) antibody NB100-2339 used at 0.1 ug/ml. To examine total MCM2, the membrane was stripped and blotted with A300-191A at 0.1 ug/ml. For blotting immunoprecipitated MCM2, the ReliaBLOT Reagents and Procedures were used. Detection: Chemiluminescence with exposure times of 10 seconds (A and B).

Immunohistochemistry

Supportive validation

Submitted by

Novus Biologicals (provider)

Main image

Experimental details

Immunohistochemistry: MCM2 [p Ser53] Antibody [NB100-2339] - Sample: FFPE sections of human breast carcinoma (left) and mouse renal cell carcinoma (right). Antibody: Affinity purified rabbit anti-fs18 phospho MCM2 (S53) fs20 used at a dilution of 1:200 (1ug/ml). Detection: DAB